International Journal of Drug Policy
Volume 19, Issue 6 , Pages 450-458 , December 2008

Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia

  • Adam R. Winstock

      Affiliations

    • Sydney South West Area Health Service, Drug Health Services, Locked Bag 4002, Ashfield, NSW 2131, Australia
    • Corresponding Author InformationCorresponding author. Tel.: +61 2 9378 1314; fax: +61 2 9378 1338.
    • ,
  • Toby Lea

      Affiliations

    • Sydney South West Area Health Service, Drug Health Services, Locked Bag 4002, Ashfield, NSW 2131, Australia
    • ,
  • Janie Sheridan

      Affiliations

    • School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, New Zealand

Received 10 January 2007 ,Revised 28 March 2007 ,Accepted 29 March 2007.

References 

  1. Aquilino WS. Interview mode effects in surveys of drug and alcohol use: A field experiment. Public Opinion Quarterly. 1994;58:210–240
  2. Bell J, Burrell T, Indig D, Gilmour S. Cycling in and out of treatment; participation in methadone treatment in NSW 1990–2002. Drug and Alcohol Dependence. 2006;81:55–61
  3. Best D, Gossop M, Lehmann P, Marsden J, Farrell M, Strang J. Eating too little, smoking and drinking too much: Wider lifestyle problems among methadone maintenance patients. Addiction Research. 1998;6:489–498
  4. Caplehorn JRM, Drummer OH. Fatal methadone toxicity: Signs and circumstances, and the role of benzodiazepines. Australian and New Zealand Journal of Public Health. 2002;26:358–363
  5. Cazorla C, Grenier De Cardenal D, Schuhmacher H, Thomas L, Wack A, May T, et al. Infectious complications and misuse of high-dose buprenorphine. Presse Medicale. 2005;34:719–724
  6. Cicero TJ, Inciardi JA, Munoz A. Trends in abuse of OxyContin and other opioid analgesics in the United States: 2002–2004. The Journal of Pain. 2005;6:662–672
  7. Cole BE. Recognizing and preventing medication diversion. Family Practice Management. 2001;8:37–41
  8. Darke S, Ross J, Hall W. Prevalence and correlates of the injection of methadone syrup in Sydney, Australia. Drug and Alcohol Dependence. 1996;43:191–198
  9. Darke S, Topp L, Ross J. The injection of methadone and benzodiazepines among Sydney injecting drug users 1996–2000: 5-Year monitoring of trends from the Illicit Drug Reporting System. Drug and Alcohol Review. 2002;21:27–32
  10. Eissenberg T, Johnson RE, Bigelow GE, Walsh SL, Liebson IA, Strain EC, et al. Controlled opioid withdrawal evaluation during 72h dose omission in buprenorphine-maintained patients. Drug and Alcohol Dependence. 1997;45:81–91
  11. Feeney GFX, Fairweather P. Groin tissue necrosis requiring skin graft following parenteral abuse of buprenorphine tablets. Drug and Alcohol Review. 2003;22:359–361
  12. Fountain J, Strang J, Gossop M, Farrel M, Griffiths P. Diversion of prescribed drugs by drug users in treatment: Analysis of the UK market and new data from London. Addiction. 2000;95:393–406
  13. Fraser S. Diversion and injection of opioid pharmacotherapies in Australia: How and why and what role for policy?. In: Paper presented at the APSAD conference 2006. Cairns, Australia. 2006;
  14. Gmel G. The effect of mode of data collection and of non-response on reported alcohol consumption: A split-sample study in Switzerland. Addiction. 2000;95:123–134
  15. Gossop M, Marsden J, Stewart D, Kidd T. The National Treatment Outcome Research Study (NTORS): 4–5 year follow-up results. Addiction. 2003;98:291–303
  16. Guichard A, Lert F, Calderon C, Gaigi H, Maguet O, Soletti J, et al. Illicit drug use and injection practices among drug users on methadone and buprenorphine maintenance treatment in France. Addiction. 2003;98:1585–1597
  17. Hailstone S, Indig D, Lawrance A, Gill T, Anns M. Prescription methadone takeaway doses in NSW: Audit and follow up intervention. In: Paper presented at the APSAD conference 2004. Perth, Australia. 2004;
  18. Hopwood M, Southgate E, Kippax S, Bammer G, Isaac-Toua G, MacDonald M. The injection of methadone syrup in New South Wales: Patterns of use and increased harm after partial banning of injecting equipment. Australian and New Zealand Journal of Public Health. 2003;27:551–555
  19. Horyniak D, Armstrong S, Higgs P, Wain D, Aitken C. Buprenorphine injection in Melbourne: Views from current injectors. In: Paper presented at the APSAD conference 2006. Cairns, Australia. 2006;
  20. Humeniuk R, Ali R, McGregor C, Darke S. Prevalence and correlates of intraveneous methadone syrup administration in Adelaide, Australia. Addiction. 2003;98:413–418
  21. Jenkinson RA, Clark NC, Fry CL, Dobbin M. Buprenorphine diversion and injection in Melbourne, Australia: An emerging issue?. Addiction. 2005;100:197–205
  22. Kintz P. Deaths involving buprenorphine: A compendium of French cases. Forensic Science International. 2001;121:65–69
  23. Kintz P. A new series of 13 buprenorphine-related deaths. Clinical Biochemistry. 2002;35:513–516
  24. Kraus L, Augustin R. Measuring alcohol consumption and alcohol-related problems: Comparison of responses from self-administered questionnaires and telephone interviews. Addiction. 2001;96:459–471
  25. Lauzon P, Vincelette J, Bruneau J, Lamothe F, Lachance N, Brabant M, et al. Illicit use of methadone among i.v. drug users in Montreal. Journal of Substance Abuse Treatment. 1994;11:457–461
  26. Lintzeris N, Lenne M, Ritter A. Methadone injecting in Australia: A tale of two cities. Addiction. 1999;94:1175–1178
  27. Mattick, R. P., Digiusto, E., Doran, C. M., OBrien, S., Shanahan, M., Kimber, J., et al. (2001). National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD): Report of results and recommendations. Sydney: National Drug and Alcohol Research Centre.
  28. McCormick CG. Regulatory challenges for new formulations of controlled substances in today's environment. Drug and Alcohol Dependence. 2006;83(Suppl. 1):S63–S67
  29. Nielsen S, Dietze P, Dunlop A, Muhleisen P, Lee N, Taylor D. Buprenorphine supply by community pharmacists in Victoria, Australia: Perceptions, experiences and key issues identified. Drug and Alcohol Review. 2007;26:143–151
  30. NSW Department of Health . New South Wales opioid treatment program clinical guidelines for methadone and buprenorphine treatment of opioid dependence. Sydney: NSW Department of Health; 2006;
  31. NSW Health Department . NSW policy for the use of buprenorphine in the treatment of opioid dependence. Sydney: NSW Health Department; 2001;
  32. Pani PP, Pirastu R, Ricci A, Gessa GL. Prohibition of take-home dosages: Negative consequences on methadone maintenance treatment. Drug and Alcohol Dependence. 1996;41:81–84
  33. Perret G, Deglon JJ, Kreek MJ, Ho A, La Harpe R. Lethal methadone intoxications in Geneva, Switzerland, from 1994 to 1998. Addiction. 2000;95:1647–1653
  34. Pharmaceutical Services Branch . Supply of methadone and buprenorphine under the New South Wales pharmacotherapy drug treatment programs: Guidelines for community pharmacists. Sydney: NSW Health Department; 2004;
  35. Pirnay S, Borron SW, Giudicelli CP, Tourneau J, Baud FJ, Ricordel I. A critical review of the causes of death among post-mortem toxicological investigations: Analysis of 34 buprenorphine-associated and 35 methadone-associated deaths. Addiction. 2004;99:978–988
  36. Rhoades HM, Creson D, Elk R, Schmitz J, Grabowski J. Retention, HIV risk, and illicit drug use during treatment: Methadone dose and visit frequency. American Journal of Public Health. 1998;88:34–39
  37. Ritter A, Di Natale R. The relationship between take-away methadone policies and methadone diversion. Drug and Alcohol Review. 2005;24:347–352
  38. Robinson GM, Kemp R, Lee C, Cranston D. Patients in methadone maintenance treatment who inject methadone syrup: A preliminary study. Drug and Alcohol Review. 2000;19:447–450
  39. Ross J, Teesson M, Darke S, Lynskey M, Ali R, Ritter A, et al. The characteristics of heroin users entering treatment: Findings from the Australian Treatment Outcome Study (ATOS). Drug and Alcohol Review. 2005;24:411–418
  40. Schifano F, Corkery J, Gilvarry E, Deluca P, Oyefeso A, Ghose AH. Buprenorphine mortality, seizures and prescription data in the UK 1980–2002. Human Psychopharmacology. 2005;20:343–348
  41. Shah N, Lathrop SL, Landen MG. Unintentional methadone-related overdose death in New Mexico (USA) and implications for surveillance 1998–2002. Addiction. 2005;100:176–188
  42. Stafford, J., Degenhardt, L., Black, E., Bruno, R., Buckingham, K., Fetherston, J., et al. (2005). Australian drug trends 2005: Findings from the Illicit Drug Reporting System (IDRS). National Drug and Alcohol Research Centre Monograph No. 59.
  43. Strang J, Marsden J, Cummins M, Farrell M, Finch E, Gossop M, et al. Randomized trial of supervised injectable versus oral methadone maintenance: Report of feasibility and 6-month outcome. Addiction. 2000;95:1631–1645
  44. Sunjic S, Howard J. “Non-injectables”: Methadone syrup and benzodiazepine injection by methadone-maintained clients. Drug and Alcohol Review. 1996;15:245–250
  45. Treloar C, Fraser S, Valentine K. Valuing methadone takeaway doses: The contribution of service user perpectives to policy and practice. Drugs: Education, Prevention and Policy. 2007;14:61–74
  46. Vidal-Trecan G, Varescon I, Nabet N, Boissonnas A. Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug and Alcohol Dependence. 2003;69:175–181
  47. Walsh SL, Preston KL, Bigelow GE, Stitzer ML. Acute administration of buprenorphine in humans: Partial agonist and blockade effects. Journal of Pharmacology and Experimental Therapeutics. 1995;274:361–372
  48. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clinical Pharmacology and Therapeutics. 1994;55:569–580
  49. Winstock AR, Bell J. Clinical guidelines assessing suitability for unsupervised medication doses for treating opioid dependency. Royal Australasian College of Physicians and Australasian Chapter of Addiction Medicine; 2006;
  50. Winstock AR, Lea T, Madden A, Bath N. Satisfaction guaranteed? What opioid pharmacotherapy clients think about their treatment.. In: Paper presented at the APSAD conference 2006. Cairns, Australia. 2006;
  51. Winstock, A. R., Lea, T., Madden, A., & Bath, N. (in press). Knowledge about buprenorphine and methadone among those receiving treatment for opioid dependence. Drugs: Education, Prevention and Policy.
  52. Zador D, Sunjic S. Deaths in methadone maintenance treatment in New South Wales, Australia 1990–1995. Addiction. 2000;95:77–84

PII: S0955-3959(07)00087-4

doi: 10.1016/j.drugpo.2007.03.002

International Journal of Drug Policy
Volume 19, Issue 6 , Pages 450-458 , December 2008

Article Tools